Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 58.69 USD -2.09% Market Closed
Market Cap: 119B USD
Have any thoughts about
Bristol-Myers Squibb Co?
Write Note

Bristol-Myers Squibb Co
Income to Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bristol-Myers Squibb Co
Income to Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income to Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
Bristol-Myers Squibb Co
NYSE:BMY
Income to Minority Interest
-$11m
CAGR 3-Years
18%
CAGR 5-Years
14%
CAGR 10-Years
6%
Johnson & Johnson
NYSE:JNJ
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Income to Minority Interest
-$32m
CAGR 3-Years
18%
CAGR 5-Years
-1%
CAGR 10-Years
-1%
Merck & Co Inc
NYSE:MRK
Income to Minority Interest
-$15m
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
9%
Zoetis Inc
NYSE:ZTS
Income to Minority Interest
-$8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-10%
Eli Lilly and Co
NYSE:LLY
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Bristol-Myers Squibb Co
Glance View

Market Cap
119B USD
Industry
Pharmaceuticals
Economic Moat
None

Bristol-Myers Squibb Co. (BMS) is a global biopharmaceutical company renowned for its innovative approach to discovering and developing transformative medicines. Founded over 160 years ago, BMS has built a robust portfolio that includes therapies across oncology, immunology, cardiovascular disease, and infectious diseases, focusing on addressing unmet medical needs. The company is celebrated for its substantial investments in research and development, which have led to groundbreaking treatments like Opdivo and Eliquis. These products have not only propelled revenue growth but also established BMS as a key player in the life sciences sector, showcasing its commitment to advancing the health and well-being of patients around the world. For investors, BMS presents a compelling opportunity rooted in a strong pipeline and strategic partnerships. The company has navigated recent challenges, including patent expirations, by fostering innovation and expanding its therapeutic offerings through mergers and acquisitions. In the ever-evolving healthcare landscape, BMS aims to leverage its scientific expertise and market presence to drive sustainable growth. With a focus on maintaining a balanced portfolio and a disciplined approach to capital allocation, Bristol-Myers Squibb stands out as a resilient entity poised to deliver long-term value, supported by a robust pipeline expected to bring additional blockbuster products to market in the coming years.

BMY Intrinsic Value
73.25 USD
Undervaluation 20%
Intrinsic Value
Price

See Also

What is Bristol-Myers Squibb Co's Income to Minority Interest?
Income to Minority Interest
-11m USD

Based on the financial report for Sep 30, 2024, Bristol-Myers Squibb Co's Income to Minority Interest amounts to -11m USD.

What is Bristol-Myers Squibb Co's Income to Minority Interest growth rate?
Income to Minority Interest CAGR 10Y
6%

Over the last year, the Income to Minority Interest growth was 39%. The average annual Income to Minority Interest growth rates for Bristol-Myers Squibb Co have been 18% over the past three years , 14% over the past five years , and 6% over the past ten years .

Back to Top